Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rosiglitazone and cardiovascular risk.

× No keyword cloud information.

35 in total

1. Rosiglitazone: a European regulatory perspective.

Authors: E Blind; K Dunder; P A de Graeff; E Abadie
Journal: Diabetologia Date: 2010-12-14 Impact factor: 10.122

2. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones.

Authors: D M Nathan; J B Buse; M B Davidson; E Ferrannini; R R Holman; R Sherwin; B Zinman
Journal: Diabetologia Date: 2008-01 Impact factor: 10.122

3. Medicine. Moving toward transparency of clinical trials.

Authors: Deborah A Zarin; Tony Tse
Journal: Science Date: 2008-03-07 Impact factor: 47.728

Review 4. Moving from opacity to transparency in pharmaceutical policy.

Authors: Irfan Dhalla; Andreas Laupacis
Journal: CMAJ Date: 2008-02-12 Impact factor: 8.262

Review 5. Do we learn the right things from clinical trials?

Authors: Silvio Garattini; Vittorio Bertele'
Journal: Eur J Clin Pharmacol Date: 2008-01-29 Impact factor: 2.953

6. What are the long-term cardiovascular effects of treatment with rosiglitazone?

Authors: Fiby Nessim; Lisel Loney-Hutchinson; Samy I McFarlane
Journal: Curr Diab Rep Date: 2008-06 Impact factor: 4.810

Review 7. The role of mitochondria in the pathophysiology of skeletal muscle insulin resistance.

Authors: Ines Pagel-Langenickel; Jianjun Bao; Liyan Pang; Michael N Sack
Journal: Endocr Rev Date: 2009-10-27 Impact factor: 19.871

8. Type 2 diabetes, thiazolidinediones, and cardiovascular risk.

Authors: Clare Taylor; F D Richard Hobbs
Journal: Br J Gen Pract Date: 2009-07 Impact factor: 5.386

Review 9. Systematic reviews to ascertain the safety of diabetes medications.

Authors: Michael R Gionfriddo; Oscar L Morey-Vargas; Juan P Brito; Aaron L Leppin; M Hassan Murad; Victor M Montori
Journal: Curr Diab Rep Date: 2014-04 Impact factor: 4.810

10. Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?

Authors: Ahmad Aljada; Kshitij Ashwin Shah; Shaker A Mousa
Journal: PPAR Res Date: 2009-08-19 Impact factor: 4.964